Results 131 to 140 of about 65,843 (240)

Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma

open access: yesInternational Journal of Cancer, Volume 159, Issue 2, Page 339-344, 15 July 2026.
What's new? Uveal melanoma is the most common primary intraocular cancer in adults, and up to half of patients develop metastatic disease, predominantly in the liver, where prognosis remains poor despite promising treatment options. In this study, the authors evaluated the safety and efficacy of administering systemic therapy within 40 days of liver ...
Patrick Kasteleiner   +4 more
wiley   +1 more source

Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations

open access: yesPediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider   +4 more
wiley   +1 more source

Isolated Subcarinal Lymph Node Recurrence 24 Years After Treatment for Primary Tracheal Adenoid Cystic Carcinoma. [PDF]

open access: yesRespirol Case Rep
Suzuki Y   +8 more
europepmc   +1 more source

A subset of high‐grade sarcomas with myogenic differentiation are associated with recurrent FGFR fusions

open access: yesThe Journal of Pathology: Clinical Research, Volume 12, Issue 4, July 2026.
Abstract Recurrent fusions involving FGFR1‐4 genes have been previously described in rare subsets of mostly benign chondroid and mesenchymal neoplasms involving bone and soft tissue. However, a more comprehensive analysis of sarcomas associated with FGFR fusions, including their incidence and histotypes, has not been performed.
Maximus CF Yeung   +4 more
wiley   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1433-1439, July 2026.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz   +22 more
wiley   +1 more source

Feasibility Study of Combined Systemic Therapy and Carbon‐Ion Radiotherapy for Hepatocellular Carcinoma Patients

open access: yesCancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Background Recent advances in systemic therapy, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have improved outcomes for hepatocellular carcinoma (HCC) and enabled downstaging strategies that allow subsequent local treatments. Carbon‐ion radiotherapy (CIRT) can provide excellent tumor control with minimal
Daijiro Kobayashi   +6 more
wiley   +1 more source

A Three-Step Diagnostic Strategy for Malignant Pleural Effusions. [PDF]

open access: yesCancer Med
Nuez-Zaragoza E   +17 more
europepmc   +1 more source

Hodgkin's Lymphoma Presenting With Nephrotic Syndrome and Complicated by Posterior Reversible Encephalopathy Syndrome in a Child: A Rare Multisystem Interaction

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Early recognition of nephrotic syndrome and neurological complications in pediatric Hodgkin's lymphoma is essential. This case highlights a rare association between Hodgkin's lymphoma, nephrotic syndrome, and posterior reversible encephalopathy syndrome, emphasizing the importance of multidisciplinary management and prompt blood pressure ...
Balqees Al‐Shohef   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy